

AMENDMENTS TO THE CLAIMS

Please amend the claims as set out below.

1.-26. (Cancelled)

27. **(Currently Amended)** A polynucleotide adjuvant composition comprising:

- a polyriboinosinic-polyribocytidylc acid (PIC),
- an antibiotic, and
- a positive ion,

wherein the composition contains polynucleotide adjuvant composition molecules heterogeneous for at least one of molecular weight or size, wherein the molecular weight is in a molecular weight range of from about 66,000 300,000 to 1,200,000 Daltons and wherein the size is in a molecular size range of from about 6.4 12.8 to 24.0 Svedbergs.

28. **(Currently Amended)** The polynucleotide adjuvant composition of claim 27, wherein the molecular weight range is from about 300,000 338,000 to 1,200,000 Daltons or the molecular size range is from about 42.8 13.5 to 24.0 Svedbergs .

29. **(Currently Amended)** The polynucleotide adjuvant composition of claim 27, wherein the molecular weight range is from about 66,000 to 660,000 Daltons or the molecular size range is from about 6.4 to 18.3 Svedbergs

A polynucleotide adjuvant composition comprising a polyriboinosinic-polyribocytidylc acid (PIC), an antibiotic, and a positive ion,

wherein the polynucleotide adjuvant composition has an average molecular weight equal to or greater than 338,000 Daltons or an average molecular size equal to or greater than 13.5 Svedbergs, and/or the composition excludes molecules having no significant immunogenic effect, wherein the excluded molecules have a molecular weight about or below 150,000 Daltons or molecular size about or below 9.34S.

30. (Currently Amended) ~~The polynucleotide adjuvant composition of claim 27, wherein the molecular weight range is from about 300,000 to 660,000 Daltons or the molecular size range from about 12.8 to 18.3 Svedbergs~~

wherein the polynucleotide adjuvant composition has an average molecular weight equal to or greater than 338,000 Daltons or average molecular size equal to or greater than 13.5 Svedbergs, and/or the composition excludes molecules having no significant immunogenic effect, wherein the excluded molecules have a molecular weight about or below 300,000 Daltons or molecular size of about or below 12.8S.

31. (Previously Presented) A polynucleotide adjuvant composition comprising:

a polyriboinosinic-polyribocytidylc acid (PIC),
an antibiotic, and
a positive ion,

wherein the polynucleotide adjuvant composition has an average molecular weight equal to or greater than 150,000 Daltons or have an average molecular size equal to or greater than 9.3 Svedbergs.

32. (Currently Amended) The polynucleotide adjuvant composition of claim 31, wherein the average molecular weight is equal to or greater than ~~250,000~~ 300,000 Daltons or the average molecular size is equal to or greater than ~~11.8~~ 12.8 Svedbergs.

33. (Currently Amended) The polynucleotide adjuvant composition of claim 31, wherein the average molecular weight is equal to or greater than ~~350,000~~ 338,000 Daltons or the average molecular size is equal to or greater than ~~15.3~~ 13.5 Svedbergs.

34. (Previously Presented) The polynucleotide adjuvant composition of any of claims 27 to 33, wherein the antibiotic is kanamycin, neomycin, an anthracycline, butirosin sulfate, a gentamicin, hygromycin, amikacin, dibekacin, nebramycin, metrzamide, puromycin, streptomycin, or streptozocin.

35. (Previously Presented) The polynucleotide adjuvant composition of any of claims 27 to 33, wherein the antibiotic is kanamycin, neomycin, an anthracycline, butirosin sulfate, a gentamicin, hygromycin, amikacin, dibekacin, nebramycin, metrzamide, puromycin, streptomycin, or streptozocin

and the positive ion is calcium, cadmium, lithium, magnesium, cerium, cesium, chromium, cobalt, deuterium, gallium, iodine, iron, or zinc; and wherein the positive ion is the form of an inorganic salt or an organic complex.

36. (Previously Presented) The polynucleotide adjuvant composition of any of claims 27 to 33, wherein the antibiotic is kanamycin, neomycin, an anthracycline, butirosin sulfate, a gentamicin, hygromycin, amikacin, dibekacin, nebramycin, metrzamide, puromycin, streptomycin, or streptozocin and the source of positive ions is calcium chloride, calcium carbonate, calcium fluoride, calcium hydroxide, calcium phosphates, or calcium sulfate.

37. (Previously Presented) The polynucleotide adjuvant composition of any of claims 27 to 33, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

38. (Previously Presented) A kit comprising the polynucleotide adjuvant composition of any of claims 27 to 33 and an antigenic compound, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

39. (Previously Presented) An immunogenic composition comprising the polynucleotide adjuvant composition of any of claims 27 to 33 and an antigen, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

40. (Previously Presented) An immunogenic composition comprising the polynucleotide adjuvant composition of any of claims 27 to 33 and an antigen, wherein the antibiotic is kanamycin sulfate, the positive ion is provided by calcium chloride, and the antigen is a human antigen, a non-human animal antigen, a plant antigen, bacterial antigen, a fungal antigen, a viral antigen, a parasite antigen, or a cancer antigen.

41. (Previously Presented) An immunogenic composition comprising the polynucleotide adjuvant composition of any of claims 27 to 33 and an antigen, wherein the antibiotic is kanamycin sulfate, the positive ion is provided by calcium chloride, and the antigen is a rabies antigen.

42. (Previously Presented) An immunogenic composition of claim 41, wherein the antibiotic is kanamycin sulfate, the positive ion is provided by calcium chloride, and the antigen is an inactivated purified rabies antigen.

43. (Previously Presented) An immunogenic composition comprising the polynucleotide adjuvant composition of any of claims 27 to 33 and an antigen, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride, and wherein polynucleotide adjuvant composition is capable of eliciting an enhanced combined specific humoral and/or cell mediated immune response.

44. (Previously Presented) An immunogenic composition comprising the polynucleotide adjuvant composition of any of claims 27 to 33 and an antigen, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride, wherein at least one of the adjuvant composition or the immunogenic composition is in a solid form or a liquid form, wherein the liquid form is a solution or a suspension.

45. (Previously Presented) An immunogenic composition comprising the polynucleotide adjuvant composition of any of claims 27 to 33 and an antigen, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride, and wherein at least one of the adjuvant composition or the immunogenic composition is freeze-dried.

46. (Previously Presented) A method for enhancing an immune response to an antigenic compound, comprising: administering to a subject a composition comprising an antigenic compound and the polynucleotide adjuvant composition of any of claims 27 to 33, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

47. (Previously Presented) The method of claim 46, wherein said administering is by parenteral injection, intramuscular injection, intraperitoneal injection, intravenous injection, subcutaneous injection, inhalation, rectal delivery, vaginal delivery, nasal delivery, oral delivery, ophthalmic delivery, topical delivery, transdermal delivery or intradermal delivery.

48. (Previously Presented) A method of making an immunogenic composition, the method comprising: combining an antigen with the polynucleotide adjuvant composition of any of claims 27 to 33 to provide an immunogenic composition.

49. (Previously Presented) The method of claim 48, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

50. (Previously Presented) The method of claim 48, wherein the immunogenic composition is suitable for enhancing an immune response in a human.

51. (Previously Presented) The method of claim 48, wherein the immunogenic composition is suitable for enhancing an immune response in an animal.